Alagille综合征患儿临床治疗管理

doi:10.3969/j.issn.1672-5069.2021.02.003

实用肝脏病杂志 ›› 2021, Vol. 24 ›› Issue (2): 160-163.doi: 10.3969/j.issn.1672-5069.2021.02.003

Alagille综合征患儿临床治疗管理

郭丽, 宋元宗

510630 广州市暨南大学附属第一医院儿科

收稿日期:2020-12-28 出版日期:2021-03-10 发布日期:2021-04-30
通讯作者: 宋元宗,医学博士,主任医师,教授,博士生导师。暨南大学附属第一医院儿科学教研室主任,儿科主任兼新生儿科主任。教育部高等学校临床医学类专业教学指导委员会儿科学专业教学指导分委员会委员,中国医师协会新生儿科医师分会常委兼遗传性肝病专业委员会主任委员,中华医学会儿科学分会出生缺陷预防和控制委员会委员,中华医学会感染病学分会儿童肝病与感染学组委员。专业方向是胆汁淤积性肝病诊治研究。曾成功诊断国内首例琥珀酸半醛脱氢酶缺陷病、希特林缺陷病、微绒毛包涵体病、NTCP缺陷病和婴儿肝衰竭综合征I型患儿。先后主持国家自然科学基金面上项目4项和应急管理项目1项。国内外发表论文100余篇,其中SCI论文27篇,参编专著3部。E-mail: songyuanzong@vip.tom.com
作者简介:郭丽,女,39岁,医学博士。主要从事遗传性肝病诊治研究
基金资助:
国家自然科学基金资助项目(编号:81570793/81741080/81974057)

Clinical management of pediatric patients with Alagille syndrome

Guo Li, Song Yuanzong

Department of Pediatrics, First Affiliated Hospital, Jinan University, Guangzhou 510630, Guangdong Province, China

Received:2020-12-28 Online:2021-03-10 Published:2021-04-30

摘要/Abstract

关键词: Alagille综合征, 胆汁淤积, 高脂血症, 黄色瘤, 治疗

Key words: Alagille syndrome, Cholestasis, Hyperlipidemia, Xanthoma, Therapy

郭丽, 宋元宗. Alagille综合征患儿临床治疗管理[J]. 实用肝脏病杂志, 2021, 24(2): 160-163.

Guo Li, Song Yuanzong. Clinical management of pediatric patients with Alagille syndrome[J]. Journal of Practical Hepatology, 2021, 24(2): 160-163.

[1] 马艳立,宋元宗. Alagille综合征诊断治疗进展. 中国当代儿科杂志,2014, 16(11):1188-1192.
[2] Binita MK, Kathleen ML, David AP. Medical management of Alagille syndrome.J Pediatr Gastroenterol Nutr, 2010, 50(6):580-586.
[3] EDNel, AJ Terblanche. Nutritional support of children with chronic liver disease. S Afr Med J, 2015, 105(7):607.
[4] Kremer AE, Oude Elferink RP, Beuers U. Pathophysiology and current management of pruritus in liver disease. Clin Res Hepatol Gastroenterol, 2011, 35(2):89-97.
[5] Narkewicz MR, Smith D, Gregory C, et al. Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease. J Pediatr Gastroenterol Nutr, 1998, 26(1):49-55.
[6] Mela M, Mancuso A, Burroughs AK. Pruritus in cholestatic and other liver diseases. Aliment Pharmacol Ther, 2003, 17(7):857-870.
[7] Hofmann AF.Rifampicin and treatment of cholestatic pruritus. Gut, 2002, 51(5): 756-757.
[8] Kronsten V, Fitzpatrick E, Baker A. Management of cholestatic pruritus in pediatric patients with Alagille syndrome: the King’s College Hospital experience. J Pediatr Gastroenterol Nutr, 2013, 57(2):149-154.
[9] Zellos A, Roy A, Schwarz KB. Use of oral naltrexone for severe pruritus due to cholestatic liver disease in children. J Pediatr Gastroenterol Nutr, 2010, 51(6):787-789.
[10] S Ben Ameur, I Chabchoub, J Telmoudi, et al. Management of cholestatic pruritus in children with Alagille syndrome: Case report and literature review. Arch Pediatr, 2016, 23(12):1247-1250.
[11] Ayoub MD, Kamath BM. Alagille syndrome: Diagnostic challenges and advances in management. Diagnostics (Basel), 2020, 10(11):907.
[12] Schwartz R, Rehder K, Parsons DJ, et al. Intense pruritus and failure to thrive in Alagille syndrome. J Am Acad Dermatol, 2008, 58(2 Suppl):S9-11.
[13] Alves C, Braid Z. Homozygous familial hypercholesterolemia: case report of a rare cause of dyslipidemia. Pediatr Endocrinol Diabetes Metab, 2011, 17(3):162-165.
[14] Constantin AT. Statins treatment and oro-dental aspects in a case of hereditary hypercholesterolemia in a child under 6 years. Acta Endocrinol (Buchar), 2019, 15(3):378-383.
[15] Sullivan DR, Hamilton-Craig I, van Bockxmeer F, et al. INTERIM guidelines for the diagnosis and management of familial hypercholesterolaemia. Heart Lung Circ, 2012, 21(3):159-162.
[16] Flores CD , Yu YR , Miloh TA , et al. Surgical outcomes in Alagille syndrome and PFIC: A single institution's 20-year experience. J Pediatr Surg, 2018, 53(5):976-979.
[17] Wang KS, Tiao G, Bass LM, et al. Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis. Hepatology, 2017, 65(5):1645-1654.
[18] Ramachandran P , Shanmugam N P , Sinani S A , et al. Outcome of partial internal biliary diversion for intractable pruritus in children with cholestatic liver disease. Pediat Surg Int, 2014, 30(10):1045-1049.
[19] Emerick KM, Rand EB, Goldmuntz E, et al. Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology, 1999, 29(3):822-829.
[20] Hoffenberg EJ, Narkewicz MR, Sondheimer JM, et al. Outcome of syndromic paucity of interlobular bile ducts (Alagille syndrome) with onset of cholestasis in infancy. J Pediatr, 1995, 127(2):220-224.
[21] Lykavieris P, Hadchouel M, Chardot C, et al. Outcome of liver disease in children with Alagille syndrome: a study of 163 patients. Gut, 2001, 49(3):431-435.
[22] Quiros-Tejeira RE, Ament ME, Heyman MB, et al. Variable morbidity in Alagille syndrome: a review of 43 cases. J Pediatr Gastroenterol Nutr, 1999, 29(4):431-437.
[23] Kamath BM, Podkameni G, Hutchinson AL, et al. Renal anomalies in Alagille syndrome: A disease-defining feature. Am J Med Genet A, 2012,158A(1):85-89.
[24] 沈丛欢, 马恩斯, 陶一峰,等. 儿童肝移植治疗Alagille综合征的疗效分析. 中华移植杂志(电子版), 2020,14(1):34-37.
[25] McElhinney DB, Krantz ID, Bason L, et al. Analysis of cardiovascular phenotype and genotype-phenotype correlation in individuals with a JAG1 mutation and/or Alagille syndrome. Circulation, 2002, 106(20):2567-2574.
[26] Saidi AS, Kovalchin JP, Fisher DJ, et al. Balloon pulmonary valvuloplasty and stent implantation. For peripheral pulmonary artery stenosis in Alagille syndrome. Tex Heart Inst J, 1998, 25(1):79-82.
[27] Emily Ruckdeschel, Yuli Y Kim. Pulmonary valve stenosis in the adult patient: pathophysiology, diagnosis and management. Heart, 2019, 105(5):414-422.
[28] Cuypers JAAE, Witsenburg M, van der Linde D, et al. Pulmonary stenosis: update on diagnosis and therapeutic options. Heart, 2013, 99(5):339-347.
[29] Gandhi SK, Reyes J, Webber SA, et al. Case report of combined pediatric heart-lung-liver transplantation. Transplantation, 2002, 73(12):1968-1969.
[30] Di Pinto D, Adragna M. Renal manifestations in children with Alagille syndrome. Arch Argent Pediatr, 2018, 116(2):149-153.
[31] Lennert T, Tetzner M, Er M, et al. Multicystic renal dysplasia: nephrectomy versus conservative treatment. Contrib Nephrol, 1988, 67:183-187.
[32] Chen RY, Chang H. Renal dysplasia. Arch Pathol Lab Med, 2015, 139(4):547-551.
[33] Neild GH, Thomson G, Nitsch D, et al. Renal outcome in adults with renal insufficiency and irregular asymmetric kidneys. BMC Nephrol, 2004, 5:12.
[34] Bagga A, Sinha A. Renal tubular acidosis. Indian J Pediatr, 2020, 87(9):733-744.
[35] Hingorani M, Nischal KK, Davies A, et al. Ocular abnormalities in Alagille syndrome. Ophthalmology, 1999,106(2):330-337.
[36] Nischal KK , Hingorani M , Bentley CR , et al. Ocular ultrasound in Alagille syndrome: a new sign. Ophthalmology, 1997, 104(1):79.
[37] Chang MY, Pineles SL. Optic disc drusen in children. Surv Ophthalmol, 2016, 61(6):745-758.
[38] Wagley Y, Mitchell T, Ashley J, et al. Skeletal involvement in Alagille syndrome. In Alagille Syndrome. Springer: Cham, Switzerland, 2018:121-136.

Alagille综合征患儿临床治疗管理

Clinical management of pediatric patients with Alagille syndrome

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	袁平戈, 陈文雯. 非酒精性脂肪性肝炎新药研发临床思考[J]. 实用肝脏病杂志, 2021, 24(3): 305-307.
[2]	徐文婷, 张继红, 韦冬珏, 李巍. 替诺福韦补救治疗rtM204位点突变的慢性乙型肝炎患者效果研究[J]. 实用肝脏病杂志, 2021, 24(3): 335-338.
[3]	王雪, 瞿发林, 戚伟利, 钱薇. 慢性乙型肝炎患者外周血Treg/Th17比值平衡及其对替比夫定治疗效果的影响[J]. 实用肝脏病杂志, 2021, 24(3): 339-342.
[4]	陈熙, 王玮, 高健伟, 许乐. 合并非酒精性脂肪性肝病对恩替卡韦治疗慢性乙型肝炎患者抗病毒疗效的影响[J]. 实用肝脏病杂志, 2021, 24(3): 343-346.
[5]	裴旭东, 张晓虎, 褚桂克, 李延玲, 赵萍, 王立坤, 陈新菊. 消脂祛浊方治疗合并肥胖的痰湿型非酒精性单纯性脂肪肝患者临床效果初步研究[J]. 实用肝脏病杂志, 2021, 24(3): 355-358.
[6]	齐玫, 张瑞金, 田树萍, 于艳华. 平均血小板体积对自身免疫性肝炎患者治疗不应答的预测价值分析[J]. 实用肝脏病杂志, 2021, 24(3): 371-374.
[7]	王云强, 王丽萍, 黄冬梅, 王艳彬, 刘晓杰, 李明宇, 赵欣宇. 经颈静脉肝内门体静脉分流术治疗乙型肝炎肝硬化门脉高压症患者疗效和血流动力学变化分析[J]. 实用肝脏病杂志, 2021, 24(3): 399-402.
[8]	伍畅, 张远安, 彭春芬. 内镜下套扎术后应用卡维地洛治疗肝硬化并发食管胃底静脉曲张破裂出血患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(3): 403-406.
[9]	赵凯, 薛晋峰, 薛鹏飞, 常鹏. Viatorr覆膜支架用于TIPS术治疗肝硬化门静脉高压症患者预后研究[J]. 实用肝脏病杂志, 2021, 24(3): 419-422.
[10]	冯浩, 吕海涛, 王子伟, 吴娟. 一步法和分步法治疗胆囊结石合并胆总管结石患者疗效及并发症分析[J]. 实用肝脏病杂志, 2021, 24(3): 435-438.
[11]	朱琳, 秦刚. 妊娠特有肝病诊治进展[J]. 实用肝脏病杂志, 2021, 24(3): 449-452.
[12]	张鑫赫, 田昊宇, 李异玲. 原发性胆汁性胆管炎治疗现状[J]. 实用肝脏病杂志, 2021, 24(3): 453-456.
[13]	贺宇峰, 钟晓妮, 黄建溶, 赖思奇. 替诺福韦酯与恩替卡韦治疗慢性乙型肝炎患者疗效和血清成纤维细胞生长因子-23水平变化[J]. 实用肝脏病杂志, 2021, 24(2): 200-203.
[14]	聂柳, 彭罕鸣, 廖东亮. 泼尼松和硫唑嘌呤联合熊去氧胆酸治疗自身免疫性肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(2): 224-227.
[15]	刘云华, 笪荣峰, 徐湖波, 江应平, 谢华平. 多烯磷脂酰胆碱治疗抗结核药物所致肝损伤患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(2): 228-231.